Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.
Press releases published on April 10, 2025
Eyenovia Provides Development Update on Optejet User Filled Device (UFD)
GlobeNewswire
·
April 10, 2025
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication …
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
GlobeNewswire
·
April 10, 2025
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, …
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
GlobeNewswire
·
April 10, 2025
GT-02287 oral presentation demonstrates new evidence of disease-modifying capacity in GBA1 and idiopathic Parkinson’s disease models Enrollment update provided for Phase 1b study Phase 1b study ongoing to assess safety, tolerability, pharmacokinetics, and …
Dr. Mahmoud Aljurf, First Non-US Physician to win Weinberger Prize by American College of Physicians
GlobeNewswire
·
April 10, 2025
RIYADH, Saudi Arabia, April 10, 2025 (GLOBE NEWSWIRE) -- Dr. Mahmoud Aljurf, M.D., MACP, Director of the Adult Stem Cell Transplantation and Cellular Therapy Program King Faisal Specialist Hospital …
Merakris Therapeutics Appoints Roger Ilagan to Chief Scientific Officer
GlobeNewswire
·
April 10, 2025
RESEARCH TRIANGLE PARK, N.C., April 10, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics has named Roger Ilagan, PhD as its new Chief Scientific Officer (CSO). Responsible for guiding the biologic drug development of first-in-class wound care technology that …
The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to a fine for a securities market information offence
GlobeNewswire
·
April 10, 2025
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 10 APRIL 2025 at 13.15 EEST The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to a fine for a …
Helsingin hovioikeus tuomitsi Orionin hallituksen jäsenen sakkorangaistukseen arvopaperimarkkinoita koskevasta tiedottamisrikoksesta
GlobeNewswire
·
April 10, 2025
ORION OYJ PÖRSSITIEDOTE – MUUT PÖRSSIN SÄÄNTÖJEN NOJALLA JULKISTETTAVAT TIEDOT 10.4.2025 KLO 13.15 Helsingin hovioikeus tuomitsi Orionin hallituksen jäsenen sakkorangaistukseen arvopaperimarkkinoita koskevasta …
Keros Therapeutics Announces Review of Strategic Alternatives
GlobeNewswire
·
April 10, 2025
Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on …
Curium strengthens its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis
GlobeNewswire
·
April 10, 2025
The acquisition of Nucleis will: Enhance Curium’s PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western Europe Improve reliability and accessibility of life-saving PET diagnostics for patients in Benelux and …
Neue Imprivata Studie: Mehr als die Hälfte aller befragten deutschen Unternehmen von Cybervorfällen aus der Lieferkette betroffen
GlobeNewswire
·
April 10, 2025
LANGENFELD, Deutschland, April 10, 2025 (GLOBE NEWSWIRE) -- Eine Studie des Ponemon Institutes gemeinsam mit Imprivata ergab, dass 51 Prozent der befragten deutschen Unternehmen einen Datenverlust oder eine Cyberattacke als Folge eines …
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
GlobeNewswire
·
April 10, 2025
ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation …